A PARP-inhibitor payload attaches a repair-targeting drug to an antibody. A published preclinical abstract describes a TROP2 conjugate carrying a PARP1-selective inhibitor.
The AACR 2025 abstract describes a TROP2 antibody joined through a cleavable linker to a PARP1-selective inhibitor. Cell comparisons included the conjugate, free payload and antibody alone; a breast-cancer xenograft experiment compared their activity and blood-cell effects. The reported activity varied between tested cell models, illustrating that more delivery antigen is not sufficient to establish payload sensitivity. This is a conference-abstract proof of concept, not clinical evidence that antibody delivery reverses PARP resistance or removes systemic toxicity.
Shares ADC analytes and exposure, Synthetic lethality, Antibody-drug conjugate (ADC).
Shares Synthetic lethality, PARP inhibitors, PARP.
Shares ADC analytes and exposure, Antibody-drug conjugate (ADC).
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP, Antibody-drug conjugate (ADC).
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Shares PARP inhibitors, PARP.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/